Subjects receiving any investigational drug concurrently.
Subjects receiving any investigational drug concurrently.
Participants may not be receiving any other study agents concurrently with the study drugs
Subject is enrolled (concurrently) in another investigational study, with the exception of the follow-up period of another investigational study in which no anti-cancer therapy is being administered and where only data are being collected;
Patients who are receiving any other investigational agents concurrently; palliative radiation therapy will be allowed as long as the patient meets all other eligibility criteria
Patients who are receiving any other investigational agents concurrently
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Participants receiving any other study agents concurrently with the study drugs
Patients who are receiving any other investigational agents concurrently
Patients who are concurrently receiving any other investigational agents
Patients who are receiving any other investigational agents concurrently
Have received treatment within 21 days of the initial dose of olaratumab with an investigational product or non-approved use of a drug or device or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
Subjects may not be enrolled concurrently on other treatment studies
Subjects concurrently receiving any other investigational agents within 2 weeks prior to the first study treatment
Patients must be candidates for neoadjuvant paclitaxel chemotherapy by their treating oncologist; no other investigational or commercial therapeutic agents may be given concurrently with the paclitaxel
Participation in another investigational drug trial concurrently or within 30 days of Cycle 1 Day 1, or a vaccine trial within 90 days of Cycle 1 Day 1
Patient is concurrently receiving chemotherapy, biologics, immunotherapy for cancer treatment; systemic anti-cancer treatment or investigational treatment
Subjects must not be concurrently receiving disease-modifying therapy in another therapeutic investigational study
Currently enrolled in, or discontinued within the last 14 days from a clinical trial involving an investigational product or non-approved use of a drug, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
Patient is concurrently using other anti-cancer therapy.
Treatment with another investigational agent currently or within 21 days prior to enrollment; patients may participate in other non-treatment studies concurrently if it will not interfere with participation in this study
Patients who concurrently use hormonal therapy and/or concurrent radiation therapy
Patients may not be on any other treatments for their cancer aside from those included in the protocol; patients may not undergo another form of treatment concurrently with this study
Patient may not be concurrently enrolled in another investigational drug treatment study
Participation in another investigational trial concurrently or within 30 days
Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within 2 weeks of starting study treatment with sonidegib
Patients concurrently taking the following drugs are excluded: mycophenolate, cyclosporine, prednisone > 20 mg/day, or immunosuppressive agents
Patients may NOT concurrently be on biologic therapy such as etanercept, adalimumab, alefacept, infliximab, rituximab or rilonacept; if there is a history of use of biologic agents, there must be a washout period of at least 3 half-lives prior to study initiation
Participation in another investigational study concurrently or use of another investigational drug within 6 months prior to administration of the first study vaccination;
Patients concurrently taking the following drugs are excluded: mycophenolate, cyclosporine, prednisone > 20 mg/day, or immunosuppressive agents
Steroids are not permitted 3 days prior to T cell infusion and concurrently during therapy.
Patients concurrently receiving any other investigational agents
Patient may not be concurrently enrolled in another investigational drug treatment study
Steroids are not permitted 3 days prior to T cell infusion and concurrently during therapy
Patient is concurrently using other anti-cancer therapy. All anti-cancer therapy must be discontinued prior to day one of study treatment.
Enrollment concurrently in another investigational drug study or within 4 weeks of registration
Participation in other investigational studies concurrently if these therapies include a therapeutic intervention
Investigational drug use within 28 days of the first dose of PLX3397 or concurrently
Subjects who are concurrently receiving any other investigational agents
Patient is concurrently using other approved or investigational antineoplastic agent
Patients who are receiving any other investigational agents or anticancer therapy concurrently or within 4 weeks (ie 28 days)
concurrently use other anticancer or experimental treatments
Patient is concurrently using other approved or investigational antineoplastic agent
Patients may not be on any other treatments for their cancer aside from those included in the protocol. Patients may not undergo another form of treatment concurrently with this study. Oncology supportive treatments such as growth factors, bone modifying agents, pain or nausea management are allowed.
Concurrently using fibrin sealants or other anastomosis care devices
Patient is concurrently using other approved or investigational antineoplastic agent
Subjects may not be receiving any other study agents concurrently while on this study
Patient is concurrently using other approved or investigational antineoplastic agents
Patients may not be receiving any other investigational agents concurrently with study treatment
Steroids are not permitted 3 days prior to T cell infusion and concurrently during therapy
Patients may not be on any other treatments for their cancer aside from those included in the protocol; patients may not undergo another form of treatment concurrently with this study
Participants may not be receiving any other study agents concurrently with the study drugs
Patient is concurrently using other anti-cancer therapy.
Concurrently receiving treatment with calcineurin-inhibitor plus sirolimus (either agent alone is acceptable).
Investigational drug use within 28 days of the first dose of PLX3397 or concurrently.
An investigational drug administered for the diagnosis of seminoma given concurrently or within four weeks of the first fraction of proton therapy administration
Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently
Patient concurrently has another primary malignant disease, which requires systemic treatment (chemotherapy or radiation)
Use of any other type of investigational agent or treatment concurrently or within 28 days before the first dose of study treatment
Patients who are concurrently participating in any other experimental studies that could affect the primary endpoint of this study
Patients may not be on any other treatments for their cancer aside from those included in the protocol; patients may not undergo another form of treatment concurrently with this study
Patients who are receiving any other investigational agents concurrently
Is concurrently enrolled in another therapeutic clinical trial involving ongoing therapy with any investigational or marketed product or placebo.
Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within 2 weeks of starting LDE225
Patients must have had endocrine therapy initiated or planned for >= 5 years; endocrine therapy can be given concurrently or following RT
Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy, or radiotherapy) concurrently or within 2 weeks of starting treatment
Patient who is concurrently using any other approved or investigational anti-neoplastic agent
Concurrently enrolled in another clinical study, except for non-interventiona observational studies, or if in a follow up period from a previous study
Concurrently receiving any other concomitant anticancer or experimental drug therapy
Treatment with another investigational agent currently or within 14 days prior to enrollment; patients may participate in other non-treatment studies concurrently if it will not interfere with participation in this study
Patient is concurrently using other approved or investigational antineoplastic agent
Patients with multiple osseous sites are eligible; however should not treat more than 3 separate radiation treatment fields concurrently
Currently receiving or expected to start cytotoxic chemotherapy or immunotherapy within 1 week of study enrollment and additional dexamethasone cannot be used concurrently as per attending oncologist.
Use of an investigational agent for pain control concurrently or within the past 30 days
Additional ADT agents may be concurrently administered (abiraterone, bicalutamide, enzalutamide, etc.)
Participation in another investigational trial concurrently or within 30 days
May be concurrently receiving endocrine or HER2 directed therapy
Use of an investigational agent for pain control concurrently or within the past 30 days
Patient is concurrently using other approved or investigational antineoplastic agents
Patients may concurrently participate in other therapeutic clinical trials
Receiving any agent concurrently with CLT-008 infusion which inhibits cell division (e.g., methotrexate or hydroxyurea)
Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within 2 weeks of starting treatment with LDE225
Participants may not be concurrently receiving any other study agents
Has been treated with an investigational agent within 30 days or six half-lives of its biologic activity whichever is longer, before the start of study. (Patients may not be concurrently enrolled on another trial or concurrently treated with another investigational agent)
Planned curative intent chemotherapy, delivered either concurrently or sequentially in combination with radiotherapy
Participation in another investigational drug trial either concurrently or 30 days prior to surgery
Patients may not be concurrently enrolled to another clinical trial for the treatment of cancer; co-enrollment to biospecimen studies is allowed; patients may be enrolled to other clinical trials after completing all of the baseline interventions and measures
Patients who are or will be taking other unapproved (i.e. not cleared/approved by the\n             FDA) anti-neoplastic therapies concurrently are not eligible (exception: ET with\n             everolimus is acceptable).
